# Glp1 Pancreatobiliary Risk Monitor

> Assess and monitor pancreatobiliary risk (acute pancreatitis, cholelithiasis, cholecystitis, lipase/amylase elevations) in patients on GLP-1 receptor agonists. Use when a clinician asks about gallstone risk on semaglutide/liraglutide/tirzepatide, "GLP-1 and pancreatitis", lipase elevation interpretation, prophylactic ursodeoxycholic acid, or whether to start a GLP-1 in a patient with prior pancreatitis or gallbladder disease. Grounded in Gorgojo-Martínez 2023 §5.

- Skill: `dromlakhani/glp1-pancreatobiliary-risk-monitor` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/glp1-pancreatobiliary-risk-monitor`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/glp1-pancreatobiliary-risk-monitor/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/glp1-pancreatobiliary-risk-monitor

---


# GLP-1 Pancreatobiliary Risk Monitor

## Purpose

Pancreatobiliary AEs with GLP-1 RA are uncommon but real — especially in obesity (higher relative risk than in T2D). This skill triages who needs extra caution, which biochemistry to interpret carefully, and what prophylaxis to consider.

## Activation

Trigger when:
- Patient has prior pancreatitis or gallbladder disease and is being considered for GLP-1.
- Lipase or amylase is elevated on GLP-1 therapy.
- Right upper quadrant pain or biliary symptoms develop on GLP-1.
- Clinician asks about prophylactic ursodeoxycholic acid.

## Baseline Risk Numbers

- **Acute pancreatitis (AP):** < 1% across all GLP-1 RA trials.
- **Cholelithiasis:** 0–< 1% in most trials; up to ~3% in some obesity cohorts.
- **Cholecystitis:** anecdotal.
- **Meta-analysis signal:** RR 1.37 (95% CI 1.23–1.52) for gallbladder/biliary disease overall; RR **2.29** (95% CI 1.64–3.18) in obesity trials vs RR 1.27 in T2D trials. Higher dose + longer duration → higher risk.

## Mechanism (why obesity > T2D risk)

- Rapid weight loss promotes biliary lithogenicity (same mechanism as post-bariatric surgery).
- Direct GLP-1 effect on biliary secretion + gallbladder motility (delayed emptying).

## Pre-Initiation Triage

| Patient profile | Action |
|---|---|
| No prior pancreatic/biliary disease | Standard initiation; counsel on red-flag symptoms |
| Prior cholelithiasis | Consider **ursodeoxycholic acid prophylaxis** during therapy |
| Prior acute pancreatitis | Caution — share decision; only proceed if benefit clearly outweighs risk |
| Prior cholecystitis / gallbladder disease | Caution; closer monitoring |
| Active acute pancreatitis | DO NOT initiate |

## Lipase / Amylase Interpretation

- Asymptomatic elevations up to **3× ULN (lipase)** or **5× ULN (amylase)** are common on GLP-1 RA.
- These elevations are **poor predictors of AP** — do not stop the drug for asymptomatic elevation alone.
- Levels normalise after drug withdrawal.
- **Stop and investigate** only if accompanied by clinical features of pancreatitis (epigastric pain radiating to back, nausea/vomiting unrelated to titration, systemic features).

## Volume-Depletion Pitfall

- GLP-1-induced vomiting/diarrhoea → volume depletion → severe renal failure risk in vulnerable patients.
- Aggressive hydration and prompt symptom management mitigate this rare but serious complication.

## Patient Education for Pancreatitis Recognition

Tell patient to report immediately:
- Severe upper abdominal pain (epigastric, often radiating to the back).
- Pain that is constant and worsens.
- Pain accompanied by nausea/vomiting that is qualitatively different from titration AEs.
- Fever or jaundice.

## Management If Pancreatobiliary AE Develops

- Manage according to local centre protocols.
- Stop the GLP-1 RA pending workup if AP is suspected.
- Reintroduction after AP is generally not recommended.

## Rules & Constraints

1. **Don't stop the drug for asymptomatic enzyme bumps** — clinical correlation required.
2. **Ursodeoxycholic acid is for selected high-risk** (prior cholelithiasis), not universal.
3. **Obesity dose > T2D dose** carries higher pancreatobiliary risk — factor into shared decision.
4. **Always include "severe abdominal pain → call now"** in the patient brief.
5. **Volume depletion is the silent killer** — keep hydration central in any management plan.

## Reference

Gorgojo-Martínez JJ et al. *J Clin Med* 2023;12:145. §5 (Uncommon AEs), Table 3.